Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc. (AMPH)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Amphastar is a biopharmaceutical company focused on developing, manufacturing, and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Key products include BAQSIMI® (glucagon), Primatene MIST® (albuterol), and various APIs. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Net Revenues | $191,840 | $191,214 | $536,782 | $545,444 |
| Gross Profit | $98,646 | $101,941 | $270,387 | $287,207 |
| Gross Margin | 51.4% | 53.3% | 50.4% | 52.7% |
| Net Income | $17,350 | $40,429 | $73,665 | $121,555 |
| Diluted EPS | $0.37 | $0.78 | $1.52 | $2.32 |
| Operating Cash Flow (9M) | $123,252 (2025) vs $184,362 (2024) | |||
| Cash & Equivalents (Sep 30, 2025) | $216,265 | |||
| Total Debt (Sep 30, 2025) | $619,798 (Gross) |
Material Changes vs. Prior Period
- Revenue Composition Shift: Total net revenues were flat in Q3 2025 compared to Q3 2024. However, the composition changed significantly. In 2024, a portion of BAQSIMI® sales was recognized as "Other revenues" (royalty-like) under a Transition Service Agreement (TSA) with Eli Lilly. In 2025, Amphastar assumed full distribution, moving all BAQSIMI® revenue to "Product revenues." Consequently, "Other revenues" dropped to zero in 2025.
- Product Performance:
- BAQSIMI®: Product revenues increased 33% QoQ (Q3) and 63% YoY (9M) due to expanded marketing and full distribution assumption.
- Glucagon & Epinephrine: Revenues declined significantly (Glucagon -49% QoQ; Epinephrine -12% QoQ) due to pricing pressure and competition, partially offset by volume increases in epinephrine pre-filled syringes.
- Primatene MIST®: Revenues increased 11% QoQ driven by marketing efforts.
- Expense Increases:
- General & Administrative (G&A): Increased 166% in Q3 2025 ($39.5M vs $14.8M) primarily due to a $23.1 million litigation provision related to a personal injury lawsuit verdict.
- Research & Development (R&D): Increased 6% in Q3 2025, driven by a $5.3 million upfront payment for a new licensing agreement with Nanjing Anji Biotechnology.
- Profitability: Net income decreased 57% in Q3 2025 and 40% in the first nine months of 2025 compared to the prior year periods, largely due to the litigation charge and lower gross margins from pricing pressures on legacy products.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Litigation: A jury verdict in October 2025 awarded a plaintiff $34.1 million in a personal injury lawsuit. $11.0 million is covered by insurance; the remaining $23.1 million was accrued in Q3 2025 G&A expenses. The company is exploring appeal options.
- Licensing Deal: In August 2025, the company entered a license agreement with Nanjing Anji Biotechnology, paying $6.0 million in upfront/earnest payments (expensed in R&D). Future obligations include up to $42 million in development milestones and $225 million in sales milestones.
- Outlook & Strategy:
- Product Launches: Launched Iron Sucrose Injection in August 2025.
- Share Buybacks: In August 2025, the Board authorized a $50 million increase to the share buyback program. The company purchased $55.1 million of treasury stock in the first nine months of 2025.
- Capital Expenditures: Plans to significantly increase capital expenditures to expand manufacturing facilities in the U.S. and China, funded by operating cash flows.
- Risks:
- China Operations: Significant manufacturing exposure in China (APIs and starting materials) creates risks related to geopolitical tensions, tariffs, and supply chain disruptions.
- Competition: Continued pricing pressure and competition in glucagon and epinephrine markets are expected to drive revenue declines in these categories.
- Regulatory: Ongoing FDA inspections and the need for regulatory approvals for pipeline products.
Investor Verification Checklist
- Litigation Status: Verify the status of the $34.1 million personal injury lawsuit appeal and the adequacy of the $11.0 million insurance coverage.
- BAQSIMI® Growth Sustainability: Assess whether the 33% Q3 growth in BAQSIMI® is sustainable given the shift from royalty-based to full product revenue recognition.
- Legacy Product Decline: Monitor the trajectory of Glucagon and Epinephrine revenue declines to determine if pricing pressures are stabilizing.
- China Supply Chain: Review the impact of potential new tariffs or trade restrictions on the company's Chinese manufacturing facilities and API imports.
- Capital Allocation: Track the execution of the new $50 million share buyback authorization against the backdrop of increased R&D spending and capital expenditures.